A Phase 3 interventional study of LY2189265 and Exenatide in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 89 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-01-26.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 7 that started in 2010, is one of 22 in phase 3, and was the 5th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 978 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 26th largest by enrollment of the 232 interventional ones that give a count, is one of 16 that started in 2010, is one of 85 in phase 3, and was the 44th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.
During the study, if a participant developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, the participant received additional therapeutic intervention or initiation of an alternative antihyperglycemic medication following study drug discontinuation (rescue therapy). Participants who received rescue therapy were included in the analysis population, but only measurements obtained prior to the beginning of rescue therapy were included in specified analyses.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type 2 Diabetes (T2D) not well controlled on 1, 2, or 3 oral antidiabetic medications
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks
Drug: LY2189265 · Drug: Metformin · Drug: Pioglitazone
LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks
Drug: LY2189265 · Drug: Metformin · Drug: Pioglitazone
Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks
Drug: Exenatide · Drug: Metformin · Drug: Pioglitazone
Placebo: subcutaneous (SC), once weekly for 26 weeks LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52). Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks Pioglitazone: at least 30 mg/day, oral, for 52 weeks
Drug: LY2189265 · Drug: Placebo · Drug: Metformin · Drug: Pioglitazone
Also known as: Dulaglutide
Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks for Body Weight
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks for Body Weight
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks on Body Mass Index (BMI)
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks on Body Mass Index (BMI)
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles
The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles
The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 26 Weeks
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
Time frame: Baseline, 26 weeks
Percentage of Participants Attaining Glycosylated Hemoglobin (HbA1c) Less Than 7% and Less Than or Equal to 6.5% at 52 Weeks
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks in Updated Homeostasis Model Assessment of Beta-cell Function (HOMA2-%B) and Updated Homeostasis Model Assessment of Insulin Sensitivity (HOMA2-%S)
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks in the EuroQol 5
The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks in the EuroQol 5
The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version
The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). The DTSQ change version (DTSQc) was not collected at 26 weeks. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) and Change (DTSQc) Versions
The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) versions are used to assess participant treatment satisfaction at each study visit and relative change in satisfaction from baseline, respectively. Both questionnaires consist of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The change version has the same 8 items as the status version with a small alteration of the wording of Item 7. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied) for the DTSQs and from -18 (much less satisfied) to +18 (much more satisfied) for the DTSQc. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living
The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living
The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Number of Participants With Adjudicated Cardiovascular Events at 52 Weeks
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event since the previous inquiry. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Change From Baseline to 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Change in Baseline to 26 Weeks on Pulse Rate
Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change in Baseline to 52 Weeks on Pulse Rate
Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks on Blood Pressure
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks on Blood Pressure
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 52 weeks
Number of Participants With Adjudicated Pancreatitis at 26 Weeks
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Number of Participants With Adjudicated Pancreatitis at 52 Weeks
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only participants with confirmed pancreatitis during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Change From Baseline to 26 Weeks on Pancreatic Enzymes
Amylase (total and pancreas-derived) and lipase concentrations were measured.
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks on Pancreatic Enzymes
Amylase (total and pancreas-derived) and lipase concentrations were measured.
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks on Serum Calcitonin
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks on Serum Calcitonin
Time frame: Baseline, 52 weeks
Number of Self-reported Hypoglycemic Events at 26 Weeks
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Number of Self-reported Hypoglycemic Events at 52 Weeks
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Rate of Self-reported Hypoglycemic Events at 26 Weeks
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Rate of Self-reported Hypoglycemic Events at 52 Weeks
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks
Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.
Time frame: Baseline through 26 weeks
Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks
Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.
Time frame: Baseline through 52 weeks
Number of Participants With LY2189265 Antibodies at 26 Weeks
LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.
Time frame: Baseline through 26 weeks
Number of Participants With LY2189265 Antibodies at 52 Weeks and 4 Weeks After Last Dose of Study Drug
LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.
Time frame: 26 weeks through 52 weeks and 53 weeks through 4 weeks after last dose
Number of Participants With Treatment Emergent Adverse Events at 26 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks
Number of Participants With Treatment Emergent Adverse Events at 52 Weeks
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only TEAEs that occurred during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Change From Baseline to 26 Weeks in Hematological and Biochemical Lab Values
Time frame: Baseline, 26 weeks
Change From Baseline to 52 Weeks in Hematological and Biochemical Lab Values
Time frame: Baseline, 52 weeks
Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP)
Time frame: Baseline, 26 weeks
Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265
Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
Time frame: 4 weeks, 13 weeks, 26 weeks, and 52 weeks
| Milestone | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Started | 279 | 280 | 278 | 141 |
| Received at least 1 dose of study drug | 279 | 280 | 276 | 141 |
| Completed 26 weeks | 260 | 263 | 252 | 124 |
| Completed | 245 | 254 | 237 | 124 |
| Not completed | 34 | 26 | 41 | 17 |
| Withdrew: Adverse event | 9 | 4 | 10 | 3 |
| Withdrew: Death | 1 | 1 | 0 | 0 |
| Withdrew: Entry criteria not met | 3 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 7 | 10 | 13 | 5 |
| Withdrew: Physician decision | 2 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 9 | 7 | 12 | 5 |
| Withdrew: Treatment noncompliance | 1 | 1 | 1 | 0 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
| percentage of glycosylated hemoglobin | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) | -1.51 ± 0.06 | -1.30 ± 0.06 | -0.99 ± 0.06 | -0.46 ± 0.08 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate.
| percentage of glycosylated hemoglobin | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) | -1.36 ± 0.08 | -1.07 ± 0.08 | -0.80 ± 0.08 |
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
| kilograms (kg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks for Body Weight | -1.34 ± 0.25 | 0.18 ± 0.25 | -1.14 ± 0.26 | 1.37 ± 0.37 |
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
| kilograms (kg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks for Body Weight | -1.08 ± 0.34 | 0.49 ± 0.34 | -0.76 ± 0.35 |
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| kilograms per meter squared (kg/m^2) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks on Body Mass Index (BMI) | -0.48 ± 0.09 | 0.07 ± 0.09 | -0.41 ± 0.09 | 0.49 ± 0.13 |
Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| kilograms per meter squared (kg/m^2) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks on Body Mass Index (BMI) | -0.37 ± 0.12 | 0.18 ± 0.12 | -0.28 ± 0.12 |
The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
| milligrams per deciliter (mg/dL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles | -46.82 ± 1.81 | -42.09 ± 1.87 | -37.48 ± 1.83 | -18.07 ± 2.68 |
The SMPG data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening; 2 hours post-evening meal; bedtime; and 3AM or 5 hours after bedtime. Least squares (LS) means of the mean of the 8 time points (daily mean) were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit as fixed effects and baseline as a covariate.
| milligrams per deciliter (mg/dL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks for Daily Mean Blood Glucose Values From the 8-point Self-monitored Plasma Glucose (SMPG) Profiles | -43.84 ± 2.07 | -40.62 ± 2.12 | -36.16 ± 2.11 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
| percentage of participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| HbA1c Less Than 7% | 78.2 | 65.8 | 52.3 | 42.9 |
| HbA1c Less Than or Equal to 6.5% | 62.7 | 53.2 | 38.0 | 24.4 |
The percentage of participants achieving HbA1c level less than 7.0% and less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model.
| percentage of participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| HbA1c Less Than 7.0% | 70.8 | 59.1 | 49.2 |
| HbA1c Less Than or Equal to 6.5% | 57.2 | 48.3 | 34.6 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| percentage of HOMA2 | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| HOMA2-%B | 36.14 ± 2.60 | 23.61 ± 2.67 | 15.02 ± 2.62 | 0.93 ± 3.66 |
| HOMA2-%S | -3.14 ± 2.91 | 1.16 ± 2.97 | -1.59 ± 2.92 | 2.56 ± 4.07 |
The homeostatic model assessment (HOMA) quantifies insulin resistance and beta-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady-state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as percentages of a normal reference population (normal young adults). The normal reference populations were set at 100%. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| percentage of HOMA2 | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| HOMA2-%B | 35.21 ± 2.63 | 25.69 ± 2.70 | 13.57 ± 2.75 |
| HOMA2-%S | -7.48 ± 2.93 | -5.49 ± 3.01 | -3.75 ± 3.07 |
The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| VAS Health State Score (n=270, 267, 264, 119) | 4.50 ± 0.85 | 2.41 ± 0.85 | 3.94 ± 0.85 | 0.71 ± 1.15 |
| EQ-5D UK (n=270, 266, 264, 119) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.00 ± 0.01 | -0.00 ± 0.02 |
The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| VAS Health State Score (n=270, 267, 264) | 5.15 ± 0.89 | 3.52 ± 0.89 | 3.51 ± 0.89 |
| EQ-5D UK (n=270, 266, 264) | 0.02 ± 0.01 | 0.01 ± 0.01 | -0.00 ± 0.01 |
The Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) is used to assess participant treatment satisfaction at each study visit. The questionnaire consists of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied). The DTSQ change version (DTSQc) was not collected at 26 weeks. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks in the Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) Version | 2.40 ± 0.34 | 2.56 ± 0.33 | 0.85 ± 0.33 | 0.49 ± 0.45 |
The Diabetes Treatment Satisfaction Questionnaire status (DTSQs) and change (DTSQc) versions are used to assess participant treatment satisfaction at each study visit and relative change in satisfaction from baseline, respectively. Both questionnaires consist of 8 items, 6 of which (1, and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The change version has the same 8 items as the status version with a small alteration of the wording of Item 7. Scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from 0 (very dissatisfied) to 36 (very satisfied) for the DTSQs and from -18 (much less satisfied) to +18 (much more satisfied) for the DTSQc. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline score as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| DTSQs Treatment Satisfaction (n=270, 268, 266) | 2.05 ± 0.36 | 2.11 ± 0.36 | 0.69 ± 0.36 |
| DTSQc Treatment Satisfaction (n=249, 237, 226) | 15.36 ± 0.40 | 15.46 ± 0.41 | 14.01 ± 0.41 |
The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks in the Impact of Weight on Activities of Daily Living | 0.18 ± 0.27 | 0.12 ± 0.27 | 0.47 ± 0.27 | 0.03 ± 0.36 |
The Impact of Weight on Activities of Daily Living (renamed the Ability to Perform Physical Activities of Daily Living \[APPADL\]) questionnaire contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = "not at all difficult" and 1 = "unable to do". The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks in the Impact of Weight on Activities of Daily Living | 0.18 ± 0.29 | -0.18 ± 0.29 | 0.35 ± 0.29 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks on the Impact of Weight on Self-Perception | 0.56 ± 0.15 | 0.47 ± 0.15 | 0.46 ± 0.15 | 0.45 ± 0.20 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate.
| units on a scale | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks on the Impact of Weight on Self-Perception | 0.50 ± 0.15 | 0.47 ± 0.15 | 0.64 ± 0.15 |
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event since the previous inquiry. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by an external committee of physicians with cardiology expertise. Nonfatal cardiovascular AEs to be adjudicated included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions, and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with CV events confirmed by adjudication is summarized cumulatively at 52 weeks. Serious and all other non-serious adverse events regardless of causality are summarized in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Any CV Event | 3 | 2 | 2 |
| Any Fatal Event | 1 | 0 | 0 |
| Any Non-fatal CV Event | 3 | 2 | 2 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| milliseconds (msec) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| QTcF Interval (n=253, 260, 250, 120) | -1.11 ± 1.00 | 0.91 ± 0.99 | 1.21 ± 1.00 | 1.32 ± 1.33 |
| PR Interval (n=252, 259, 246, 116) | 2.35 ± 0.89 | 0.93 ± 0.88 | 1.01 ± 0.89 | -1.83 ± 1.20 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| milliseconds (msec) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| QTcF Interval (n=239, 243, 226) | 1.28 ± 1.07 | 2.30 ± 1.07 | 2.52 ± 1.10 |
| PR Interval (n=237, 243, 220) | 2.57 ± 0.96 | 0.69 ± 0.96 | -0.82 ± 0.99 |
Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change in Baseline to 26 Weeks on Pulse Rate | 2.80 ± 0.52 | 2.80 ± 0.51 | 1.18 ± 0.52 | 0.61 ± 0.70 |
Seated pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| beats per minute (bpm) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change in Baseline to 52 Weeks on Pulse Rate | 1.68 ± 0.56 | 1.56 ± 0.55 | 1.15 ± 0.56 |
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimeters of mercury (mmHg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Seated SBP (n=263, 266, 259, 127) | 0.11 ± 0.83 | -0.36 ± 0.82 | 0.06 ± 0.83 | 3.40 ± 1.13 |
| Seated DBP (n=263, 266, 259, 127) | 0.76 ± 0.55 | 0.56 ± 0.54 | -0.11 ± 0.55 | 1.25 ± 0.75 |
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimeters of mercury (mmHg) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Seated SBP (n=248, 256, 238) | 0.83 ± 0.87 | 1.62 ± 0.85 | 0.02 ± 0.88 |
| Seated DBP (n=248, 256, 238) | 0.89 ± 0.57 | 0.76 ± 0.57 | 0.02 ± 0.58 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Number of Participants With Adjudicated Pancreatitis at 26 Weeks | 0 | 0 | 0 | 0 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only participants with confirmed pancreatitis during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo/1.5 mg LY2189265 | Placebo/0.75 mg LY2189265 |
|---|---|---|---|---|---|
| Number of Participants With Adjudicated Pancreatitis at 52 Weeks | 1 | 0 | 0 | 0 | 0 |
Amylase (total and pancreas-derived) and lipase concentrations were measured.
| units per liter | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Amylase, Total (n=253, 253, 254, 127) | 12.50 ± 26.55 | 3.28 ± 24.24 | 5.56 ± 26.61 | -3.33 ± 27.51 |
| Amylase, Pancreas-derived (n=237, 247, 246, 122) | 14.81 (0.00 to 35.00) | 10.34 (-5.88 to 26.67) | 5.56 (-7.14 to 21.05) | -3.77 (-13.33 to 13.64) |
| Lipase (n=198, 203, 222, 114) | 10.34 (-7.50 to 29.41) | 0.00 (-15.91 to 23.08) | 3.94 (-10.26 to 23.08) | -9.53 (-23.33 to 6.67) |
Amylase (total and pancreas-derived) and lipase concentrations were measured.
| units per liter | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Amylase, Total (n=255, 263, 261) | 9.21 (-4.95 to 23.19) | 2.78 (-11.67 to 17.50) | 2.38 (-11.86 to 15.22) |
| Amylase, Pancreas-derived (n=236, 253, 246) | 16.67 (0.00 to 35.60) | 7.69 (-8.70 to 28.00) | 7.85 (-8.82 to 26.67) |
| Lipase (n=201, 205, 221) | 5.45 (-7.69 to 26.92) | 0.00 (-18.18 to 15.63) | 3.57 (-13.95 to 22.58) |
| picograms per milliliter (pg/mL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks on Serum Calcitonin | 0.20 ± 1.20 | 0.22 ± 1.91 | 0.05 ± 1.48 | 0.05 ± 0.89 |
| picograms per milliliter (pg/mL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks on Serum Calcitonin | 0.21 ± 1.29 | 0.05 ± 1.79 | 0.10 ± 1.67 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Severe HE | 0 | 0 | 1 | 0 |
| Documented Symptomatic HE | 31 | 25 | 146 | 4 |
| Asymptomatic HE | 26 | 95 | 51 | 5 |
| Nocturnal HE | 9 | 15 | 31 | 6 |
| Probable Symptomatic HE | 5 | 16 | 3 | 3 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Severe HE | 0 | 0 | 2 |
| Documented Symptomatic HE | 53 | 39 | 205 |
| Asymptomatic HE | 47 | 157 | 98 |
| Nocturnal HE | 20 | 29 | 57 |
| Probable Symptomatic HE | 8 | 22 | 4 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per year | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Severe HE | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.01 ± 0.12 | 0.00 ± 0.00 |
| Documented symptomatic HE | 0.22 ± 1.94 | 0.18 ± 0.97 | 1.07 ± 4.90 | 0.06 ± 0.48 |
| Asymptomatic HE | 0.19 ± 1.13 | 0.69 ± 4.74 | 0.38 ± 1.74 | 0.27 ± 2.44 |
| Nocturnal HE | 0.06 ± 0.60 | 0.19 ± 1.74 | 0.23 ± 1.16 | 0.27 ± 2.51 |
| Probable symptomatic HE | 0.04 ± 0.37 | 0.24 ± 2.44 | 0.02 ± 0.21 | 0.04 ± 0.51 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of equal to or less than millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of equal to or less than 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per year | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Severe HE | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.01 ± 0.09 |
| Documented symptomatic HE | 0.19 ± 1.23 | 0.14 ± 0.78 | 0.76 ± 3.18 |
| Asymptomatic HE | 0.17 ± 1.05 | 0.56 ± 3.57 | 0.37 ± 1.81 |
| Nocturnal HE | 0.07 ± 0.63 | 0.19 ± 1.72 | 0.21 ± 1.06 |
| Probable symptomatic HE | 0.03 ± 0.26 | 0.21 ± 2.38 | 0.02 ± 0.16 |
Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 26 Weeks | 4 | 14 | 13 | 22 |
Rescue therapy was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. Participants who had no rescue therapy within specified study period were considered as censored observations at the last available contact date up to specified study period. Time to start first new glucose-lowering intervention due to hyperglycemia ("rescue therapy") was analyzed between the groups using the semi-parametric proportional hazard regression model with treatment group and country as fixed effects and baseline glycosylated hemoglobin (HbA1c) as a covariate.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Number of Participants Requiring Rescue Therapy Due to Hyperglycemia at 52 Weeks | 10 | 27 | 31 |
LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.
| participants | 0.75 mg LY2189265 or 1.5 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|
| Number of Participants With LY2189265 Antibodies at 26 Weeks | 6 | 12 | 2 |
LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed. The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA were summarized.
| participants | 0.75 mg LY2189265 or 1.5 mg LY2189265 | Exenatide | Placebo/0.75 mg LY2189265 or 1.5 mg LY2189265 |
|---|---|---|---|
| 52 weeks | 3 | 2 | 2 |
| 4 weeks after last study dose | 1 | 0 | 1 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events at 26 Weeks | 215 | 199 | 198 | 104 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 52 weeks, with the exception of the Placebo/1.5 mg LY2189265 and Placebo/0.75 mg LY2189265 treatment groups, which include only TEAEs that occurred during treatment with LY2189265 (26 weeks through 52 weeks). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo/1.5 mg LY2189265 | Placebo/0.75 mg LY2189265 |
|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events at 52 Weeks | 226 | 220 | 221 | 47 | 41 |
| Measure | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks in Hematological and Biochemical Lab Values | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Measure | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide |
|---|---|---|---|
| Change From Baseline to 52 Weeks in Hematological and Biochemical Lab Values | NA ± NA | NA ± NA | NA ± NA |
| picograms per milliliter (pg/mL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo |
|---|---|---|---|---|
| Change From Baseline to 26 Weeks in N Terminal Pro Brain Natriuretic Peptide (NT-proBNP) | -6.77 ± 91.13 | -2.96 ± 189.94 | -3.38 ± 208.92 | -0.85 ± 133.04 |
Evaluable pharmacokinetic concentrations from the 4-week, 13-week, 26-week, and 52-week timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.
| nanogram hours per milliliter (ng*hr/mL) | 1.5 mg LY2189265 | 0.75 mg LY2189265 |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration Curve (AUC) for LY2189265 | 12383 ± 5433 | 6627 ± 2487 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.75 mg LY2189265 (Baseline Through 26 Weeks) | — | 15/280 (5.4%) | 194/280 (69.3%) |
| 1.5 mg LY2189265 (Baseline Through 26 Weeks) | — | 12/279 (4.3%) | 215/279 (77.1%) |
| Exenatide (Baseline Through 26 Weeks) | — | 15/278 (5.4%) | 196/278 (70.5%) |
| Placebo (Baseline Through 26 Weeks) | — | 12/141 (8.5%) | 103/141 (73%) |
| 0.75 mg LY2189265 (Baseline Through 56 Weeks) | — | 22/280 (7.9%) | 218/280 (77.9%) |
| 1.5 mg LY2189265 (Baseline Through 56 Weeks) | — | 18/279 (6.5%) | 228/279 (81.7%) |
| Exenatide (Baseline Through 56 Weeks) | — | 27/278 (9.7%) | 223/278 (80.2%) |
| Placebo/0.75 mg LY2189265 (26 Weeks Through 56 Weeks) | — | 6/62 (9.7%) | 47/62 (75.8%) |
| Placebo/1.5 mg LY2189265 (26 Weeks Through 56 Weeks) | — | 9/62 (14.5%) | 55/62 (88.7%) |
| Event | 0.75 mg LY2189265 (Baseline Through 26 Weeks) | 1.5 mg LY2189265 (Baseline Through 26 Weeks) | Exenatide (Baseline Through 26 Weeks) | Placebo (Baseline Through 26 Weeks) | 0.75 mg LY2189265 (Baseline Through 56 Weeks) | 1.5 mg LY2189265 (Baseline Through 56 Weeks) | Exenatide (Baseline Through 56 Weeks) | Placebo/0.75 mg LY2189265 (26 Weeks Through 56 Weeks) | Placebo/1.5 mg LY2189265 (26 Weeks Through 56 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| OsteomyelitisInfections and infestations | 0/280 | 0/279 | 0/278 | 1/141 | 1/280 | 0/279 | 0/278 | 2/62 | 0/62 |
| AnaemiaBlood and lymphatic system disorders | 0/280 | 0/279 | 0/278 | 0/141 | 0/280 | 0/279 | 0/278 | 1/62 | 0/62 |
| Acute myocardial infarctionCardiac disorders | 0/280 | 0/279 | 0/278 | 0/141 | 0/280 | 1/279 | 0/278 | 1/62 | 0/62 |
| Atrial fibrillationCardiac disorders | 0/280 | 2/279 | 0/278 | 2/141 | 0/280 | 2/279 | 0/278 | 1/62 | 1/62 |
| Coronary artery diseaseCardiac disorders | 1/280 | 0/279 | 1/278 | 1/141 | 1/280 | 0/279 | 1/278 | 1/62 | 0/62 |
| Myocardial ischaemiaCardiac disorders | 0/280 | 0/279 | 0/278 | 1/141 | 0/280 | 0/279 | 0/278 | 0/62 | 1/62 |
| Umbilical hernia, obstructiveGastrointestinal disorders | 0/280 | 0/279 | 0/278 | 0/141 | 0/280 | 0/279 | 0/278 | 0/62 | 1/62 |
| Chest painGeneral disorders | 0/280 | 0/279 | 0/278 | 1/141 | 0/280 | 0/279 | 0/278 | 0/62 | 1/62 |
| AbscessInfections and infestations | 0/280 | 0/279 | 0/278 | 1/141 | 0/280 | 0/279 | 0/278 | 0/62 | 1/62 |
| CellulitisInfections and infestations | 0/280 | 1/279 | 0/278 | 1/141 | 0/280 | 2/279 | 0/278 | 1/62 | 0/62 |
| Event | 0.75 mg LY2189265 (Baseline Through 26 Weeks) | 1.5 mg LY2189265 (Baseline Through 26 Weeks) | Exenatide (Baseline Through 26 Weeks) | Placebo (Baseline Through 26 Weeks) | 0.75 mg LY2189265 (Baseline Through 56 Weeks) | 1.5 mg LY2189265 (Baseline Through 56 Weeks) | Exenatide (Baseline Through 56 Weeks) | Placebo/0.75 mg LY2189265 (26 Weeks Through 56 Weeks) | Placebo/1.5 mg LY2189265 (26 Weeks Through 56 Weeks) |
|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 45/280 | 78/279 | 71/278 | 8/141 | 47/280 | 82/279 | 77/278 | 6/62 | 15/62 |
| VomitingGastrointestinal disorders | 17/280 | 47/279 | 30/278 | 2/141 | 17/280 | 48/279 | 34/278 | 3/62 | 5/62 |
| Oedema peripheralGeneral disorders | 13/280 | 3/279 | 11/278 | 7/141 | 15/280 | 8/279 | 17/278 | 9/62 | 3/62 |
| DiarrhoeaGastrointestinal disorders | 22/280 | 31/279 | 16/278 | 8/141 | 26/280 | 37/279 | 22/278 | 5/62 | 8/62 |
| NasopharyngitisInfections and infestations | 23/280 | 18/279 | 12/278 | 8/141 | 26/280 | 28/279 | 16/278 | 5/62 | 2/62 |
| DyspepsiaGastrointestinal disorders | 5/280 | 22/279 | 19/278 | 4/141 | 6/280 | 23/279 | 21/278 | 0/62 | 6/62 |
| HeadacheNervous system disorders | 9/280 | 20/279 | 24/278 | 8/141 | 14/280 | 26/279 | 25/278 | 5/62 | 6/62 |
| Upper respiratory tract infectionInfections and infestations | 14/280 | 12/279 | 12/278 | 6/141 | 25/280 | 16/279 | 20/278 | 5/62 | 4/62 |
| Decreased appetiteMetabolism and nutrition disorders | 14/280 | 22/279 | 8/278 | 3/141 | 15/280 | 23/279 | 9/278 | 2/62 | 3/62 |
| Urinary tract infectionInfections and infestations | 8/280 | 11/279 | 6/278 | 4/141 | 13/280 | 16/279 | 14/278 | 2/62 | 5/62 |
Participants who were randomized and received at least 1 dose of LY2189265, Exenatide, or Placebo.
| Age, Continuous(years) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 56.25 ± 9.72 | 55.79 ± 9.45 | 55.45 ± 10.15 | 54.56 ± 10.01 | 55.65 ± 9.81 |
| Sex: Female, Male(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| Female | 116 | 112 | 120 | 58 | 406 |
| Male | 163 | 168 | 156 | 83 | 570 |
| Ethnicity (NIH/OMB)(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 93 | 102 | 91 | 45 | 331 |
| Not Hispanic or Latino | 186 | 178 | 184 | 96 | 644 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 40 | 37 | 38 | 20 | 135 |
| Asian | 6 | 8 | 4 | 6 | 24 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 0 | 3 |
| Black or African American | 24 | 24 | 18 | 10 | 76 |
| White | 205 | 207 | 211 | 103 | 726 |
| More than one race | 3 | 3 | 3 | 2 | 11 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| United States | 226 | 226 | 223 | 113 | 788 |
| Mexico | 37 | 36 | 35 | 19 | 127 |
| Argentina | 16 | 18 | 18 | 9 | 61 |
| Body Weight(kilograms) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 96.22 ± 19.63 | 95.53 ± 20.56 | 97.37 ± 18.87 | 94.12 ± 19.28 | 96.04 ± 19.64 |
| Body Mass Index (BMI)(kilograms per meter squared (kg/m^2)) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 33.09 ± 5.33 | 33.00 ± 5.50 | 33.54 ± 5.36 | 32.90 ± 5.66 | 33.16 ± 5.43 |
| Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | 1.5 mg LY2189265 | 0.75 mg LY2189265 | Exenatide | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 8.10 ± 1.34 | 8.05 ± 1.24 | 8.07 ± 1.34 | 8.06 ± 1.31 | 8.07 ± 1.31 |
2 further baseline measures are reported on the registry.
The record gives a start of Feb 2010, a primary completion of Nov 2011 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 3 years 2 months after primary completion. A results delay was requested in Feb 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide